Cytyc invests in endometriosis
This article was originally published in The Gray Sheet
Executive Summary
Women's healthcare firm views a less-invasive, serum-based diagnostic test presently being developed by Valeo Medical for detecting endometriosis as having "excellent potential" to become a successful product. Cytyc announced making an equity investment in Valeo Nov. 9. A Valeo spokesperson says the firm is in preclinical development for the test, having completed feasibility studies on more than 450 human samples demonstrating acceptable levels of specificity and sensitivity. An estimated 7 mil. women suffer from endometriosis in the U.S. each year. Cytyc extended its women's health portfolio with a $325 mil. acquisition of NovaSure menorrhagia treatment manufacturer Novacept on March 1 (1"The Gray Sheet" March 8, 2004, p. 21)...